Study guide

2.2 Drug Supply Chain Security Act (DSCSA)

PTCE Pharmacy Technician Certification Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction

About the PTCE How to Use This Guide

2 Chapter 1: Medications

1.1 Generic and Brand Drug Names & Classifications 1.2 Cardiovascular and Anticoagulant Medications 1.3 Anti-Infective and Analgesic Medications 1.4 Endocrine, Respiratory, CNS, and Storage Requirements

3 Chapter 2: Federal Requirements

2.1 DEA Regulations and Controlled Substance Schedules 2.2 Drug Supply Chain Security Act (DSCSA) 2.3 FDA Regulations and Drug Recalls 2.4 HIPAA, CMEA, and Prescription Requirements

4 Chapter 3: Patient Safety and Quality Assurance

3.1 Medication Error Prevention 3.2 High-Alert and Look-Alike/Sound-Alike Medications 3.3 Patient Counseling and Communication 3.4 Quality Assurance and Continuous Quality Improvement

5 Chapter 4: Order Entry and Processing

4.1 Prescription Interpretation 4.2 Pharmacy Calculations 4.3 Inventory Management and NDC Numbers 4.4 Insurance, Billing, and Prescription Processing

2.2 Drug Supply Chain Security Act (DSCSA)

Key Takeaways Explain This Topic AI

DSCSA establishes a national track-and-trace system for prescription drugs to prevent counterfeit medications from entering the supply chain.

The enhanced, interoperable electronic tracing requirements began November 27, 2023, with an FDA stabilization period to November 27, 2024; small dispensers (the owning company has 25 or fewer full-time pharmacists and pharmacy technicians) are exempt from certain of them until November 27, 2027.

Product tracing documentation is the Transaction Information (TI) and Transaction Statement (TS); FDA says the transaction history (TH) requirement effectively ended November 27, 2023.

A suspect product is quarantined and promptly investigated; once a pharmacy determines a product is illegitimate, it notifies FDA and immediate trading partners within 24 hours.

Serialization requires unique identifiers: NDC, serial number, lot number, and expiration date on each saleable unit.

Last updated: November 2026

Quick Answer: DSCSA creates a national system for tracing prescription drugs at the package level. Pharmacies accept only products that come with transaction information (TI) and a transaction statement (TS), keep that documentation for 6 years, quarantine and investigate suspect products, and notify FDA within 24 hours after determining a product is illegitimate. DSCSA is a new knowledge area (2.6) on the 2026 PTCE, and the Federal Requirements domain rose from 12.5% to 18.75%.

The Drug Supply Chain Security Act (DSCSA) establishes requirements for an interoperable, electronic system to identify and trace prescription drugs distributed in the United States.

  • Why DSCSA Matters
  • Prevents counterfeit drugs from entering the legitimate supply chain
  • Enables rapid identification of suspect or recalled products
  • Creates accountability at every step: manufacturer → wholesaler → dispenser (pharmacy)
  • Protects patients from receiving dangerous counterfeit medications
  • Key DSCSA Terminology

Term Definition

Product Identifier The standardized numerical identifier (NDC plus a unique serial number), lot number, and expiration date, in human-readable and machine-readable form

Serialization Assigning a unique serial number to each individual saleable unit

Transaction Information (TI) Details about a specific drug transaction (product name, strength, dosage form, NDC, container size, number of containers, lot number, transaction date, shipment date, parties involved)

Transaction History (TH) A statement with the TI for each prior transaction back to the manufacturer; FDA says the requirement to provide and receive it effectively ended November 27, 2023

Transaction Statement (TS) The seller's statement that it is authorized, received the product from an authorized partner, and did not knowingly ship a suspect or illegitimate product

Suspect Product A product with reason to believe it is potentially counterfeit, diverted, or stolen; potentially intentionally adulterated so it would cause serious adverse health consequences or death; potentially the subject of a fraudulent transaction; or otherwise unfit so it would cause serious adverse health consequences or death

Illegitimate Product A product with credible evidence that it is counterfeit, diverted, or stolen; intentionally adulterated so it would cause serious adverse health consequences or death; the subject of a fraudulent transaction; or otherwise unfit so it would be reasonably likely to cause serious adverse health consequences or death

Transaction Documentation: TI and TS

When receiving prescription drugs, pharmacies must obtain product tracing documentation:

Document What It Contains

Transaction Information (TI) Product details: drug name, NDC, strength, lot number, quantity, transaction date, names of trading partners

Transaction Statement (TS) The seller's statement that it is authorized and did not knowingly ship a suspect or illegitimate product

Older materials teach "3 T's" that include Transaction History (TH) . FDA says that beginning November 27, 2023, the requirement for trading partners to provide and receive transaction history effectively ended.

Retention Requirement : Pharmacies must store the product tracing documentation they receive for 6 years .

Product Identifier Requirements

Each saleable unit must have a 2D data matrix barcode containing:

  • NDC (National Drug Code) — identifies the drug product
  • Serial Number — unique to each individual unit
  • Lot Number — identifies the manufacturing batch
  • Expiration Date — when the product expires
  • Pharmacy Verification Requirements
  • When Receiving Products
  • Accept only products from authorized trading partners (licensed or registered)
  • Ensure transaction documentation (TI and TS) accompanies the shipment
  • Check for signs of tampering or suspect characteristics
  • Suspect Product Handling

When a pharmacy determines that a product is suspect :

Quarantine the product, separated from product intended for distribution

Promptly investigate , in coordination with trading partners, to determine whether it is illegitimate (verify the lot number and product identifier, and check the transaction information; FDA exempts small dispensers from the package-level product-identifier check until November 27, 2027)

  • Clear or escalate : a cleared product may be distributed or dispensed; an illegitimate one is handled as below
  • Illegitimate Product Handling

When a pharmacy determines a product is illegitimate :

  • Quarantine and disposition it (do not dispense or sell)
  • Notify FDA and the immediate trading partners that may have received it within 24 hours of the determination
  • Retain a sample for examination if requested, and cooperate with the investigation
  • Keep records of the disposition for 6 years
  • DSCSA Timeline and 2026 Requirements

Milestone Requirement

November 27, 2023 Enhanced, interoperable package-level tracing requirements take effect; transaction history requirement ends

November 27, 2024 FDA stabilization period for electronic tracing ends

November 27, 2027 FDA exemption from certain enhanced requirements for small dispensers (the owning company has 25 or fewer full-time pharmacists and pharmacy technicians) ends; quarantine, investigation and illegitimate-product notification are not exempted

  • 2026 PTCE now tests DSCSA compliance knowledge
  • Exemptions from DSCSA

Certain products are exempt from DSCSA requirements:

  • Blood and blood components
  • Radioactive drugs and radioactive biological products
  • Imaging drugs
  • Certain IV solutions
  • Medical gases
  • Homeopathic products
  • Drugs compounded in compliance with FD&C Act section 503A or 503B